Last reviewed · How we verify
Drug: F 18 T807
Drug: F 18 T807 is a Small molecule drug developed by Tammie L. S. Benzinger, MD, PhD. It is currently in Phase 2 development. Also known as: Drug: 18F-AV-1451.
At a glance
| Generic name | Drug: F 18 T807 |
|---|---|
| Also known as | Drug: 18F-AV-1451 |
| Sponsor | Tammie L. S. Benzinger, MD, PhD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis
- A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drug: F 18 T807 CI brief — competitive landscape report
- Drug: F 18 T807 updates RSS · CI watch RSS
- Tammie L. S. Benzinger, MD, PhD portfolio CI
Frequently asked questions about Drug: F 18 T807
What is Drug: F 18 T807?
Drug: F 18 T807 is a Small molecule drug developed by Tammie L. S. Benzinger, MD, PhD.
Who makes Drug: F 18 T807?
Drug: F 18 T807 is developed by Tammie L. S. Benzinger, MD, PhD (see full Tammie L. S. Benzinger, MD, PhD pipeline at /company/tammie-l-s-benzinger-md-phd).
Is Drug: F 18 T807 also known as anything else?
Drug: F 18 T807 is also known as Drug: 18F-AV-1451.
What development phase is Drug: F 18 T807 in?
Drug: F 18 T807 is in Phase 2.
Related
- Manufacturer: Tammie L. S. Benzinger, MD, PhD — full pipeline
- Also known as: Drug: 18F-AV-1451
- Compare: Drug: F 18 T807 vs similar drugs
- Pricing: Drug: F 18 T807 cost, discount & access